Physician profile
Chris J Darrup
NPI 1134168321
$12,843.40
in general payments reported to CMS, 2019-2025
54 companies · $1,813 in 2025
The $1,813 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,822 · 2020: $1,649 · 2021: $1,935 · 2022: $1,867 · 2023: $2,104 · 2024: $1,654 · 2025: $1,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,570.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,048.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,603.82 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,479.29 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,264.53 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $991.77 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Lilly USA, LLC | $950.91 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $720.81 | 2019-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $450.44 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $415.88 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $282.95 | 2019-2025 | Verquvo, Gardasil 9, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $220.29 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $182.74 | 2022-2025 | Caplyta |
| Abbott Laboratories | $175.17 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.06 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $139.43 | 2020-2024 | Veozah |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Darrup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.